Glycosylases
Alpha-Mannosidosis is a lysosomal storage disorder caused by deficient activity of the enzyme alpha-D-mannosidase (EC 3.2.1.24). In humans it is known to be caused by an autosomal recessive genetic mutation. causes sugar build up and impairs cell function. Complete absence of functional enzyme leads to death during early childhood due to deterioration of the central nervous system. Enzyme with low residual activity leads to a milder type of the disease, with symptoms like reduced hearing, mental retardation, susceptibility to bacterial infections and skeletal deformities[1]. Miglitol (Axon 2067), an alpha-glucosidase (EC 3.2.1.20) inhibitor, is an oral antihyperglycaemic agent is indicated for the treatment of patients with type 2 diabetes mellitus[2].
[1] Adult alpha-mannosidosis: clinical progression in the absence of demyelination. A. Gutschalk,I. Harting, M. Cantz, C. Springer, K. Rohrschneider, H.M. Meinck. Neurology. 2004, 63, 1744-1746.
[2] Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus. L.J. Scott, C.M. Spencer. Drugs. 2000, 9, 521-549.
| Axon ID | Name | Description | From price | |
|---|---|---|---|---|
| 1730 | (+)-Kifunensine | α-mannosidase inhibitor | €120.00 | |
| 3181 | BI 99179 | Potent, selective and orally active inhibitor of type I fatty acid synthase (FAS) | €150.00 | |
| 3182 | BI 99990 | Negative control of BI 99179 as a selective inhibitor of type I fatty acid synthase | €130.00 | |
| 3570 | CD38 inhibitor compound 78c | Potent, specific, reversible, and uncompetitive inhibitor of CD38 | €140.00 | |
| 3517 | DSRM-3716 | Potent and selective SARM1 NADase inhibitor | €70.00 | |
| 2617 | GSK837149 | Selective inhibitor of human fatty acid synthase (FAS) | €120.00 | |
| 2067 | Miglitol | α-glucosidase inhibitor; oral anti-diabetic | €55.00 | |
| 3136 | Oseltamivir phosphate | Selective and orally available inhibitor of influenza virus neuraminidases | €50.00 | |
| 2934 | TH 5487 | Potent and selective active-site OGG1 inhibitor | €125.00 | |